BETA
Your AI-Trained Oncology Knowledge Connection!
Centering discussion on a patient case of transplant-eligible newly diagnosed multiple myeloma, expert panelists define high-risk disease and how it impacts treatment.
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Linvoseltamab Earns FDA Accelerated Approval for R/R Multiple Myeloma
Data supporting the FDA decision came from the phase 1/2 LINKER-MM1 trial.
Mitigating AEs and Protecting QOL Following Talquetamab in Multiple Myeloma
Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.
FDA Removes REMS, Lessens Requirements of Liso-cel/Ide-cel in Blood Cancers
The FDA had reduced driving and geographic restrictions to 2 weeks for patients with lymphomas and multiple myeloma receiving liso-cel and ide-cel.
Exploring the Potential Role of JAK Inhibitors in Multiple Myeloma
James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.
Etentamig Displays Durable Responses, Tolerability in R/R Multiple Myeloma
Efficacy with etentamig was comparable across prespecified subgroups with relapsed/refractory multiple myeloma, suggesting broad therapeutic benefit.
Mezigdomide Regimens Show Promise in Pretreated R/R Multiple Myeloma
Mezigdomide with dexamethasone and bortezomib or carfilzomib led to a median PFS exceeding 1 year across 3 cohorts in those with relapsed/refractory MM.